BioAge Labs, Inc. BIOA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 168.06% | 610.96% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 168.06% | 610.96% | -- | -- | -- |
| Cost of Revenue | 25.06% | 36.90% | 25.29% | -6.79% | -- |
| Gross Profit | -16.73% | -22.87% | -10.05% | 14.82% | -- |
| SG&A Expenses | 15.38% | 28.08% | 45.16% | 62.96% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.52% | 34.52% | 30.16% | 43.97% | -- |
| Operating Income | -16.36% | -24.30% | -18.65% | -35.06% | -- |
| Income Before Tax | -19.53% | -26.58% | -13.35% | -6.84% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.53% | -26.58% | -13.35% | -6.84% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.53% | -26.58% | -13.35% | -6.84% | -- |
| EBIT | -16.36% | -24.30% | -18.65% | -35.06% | -- |
| EBITDA | -16.32% | -24.27% | -18.63% | -35.10% | -- |
| EPS Basic | 71.08% | 84.57% | 90.25% | 93.95% | -- |
| Normalized Basic EPS | 71.07% | 84.57% | 90.18% | 92.65% | -- |
| EPS Diluted | 71.08% | 84.57% | 90.25% | 93.95% | -- |
| Normalized Diluted EPS | 71.07% | 84.57% | 90.18% | 92.65% | -- |
| Average Basic Shares Outstanding | 43.29% | 95.10% | 235.09% | 1,578.68% | -- |
| Average Diluted Shares Outstanding | 43.29% | 95.10% | 235.09% | 1,578.68% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |